OncoZenge AB (publ) reported earnings results for the fourth quarter ended December 31, 2022. For the fourth quarter, the company reported net loss was SEK 4.56 million compared to SEK 1.09 million a year ago. Basic loss per share from continuing operations was SEK 0.39 compared to SEK 0.09 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.955 SEK | +2.20% | +2.99% | +27.99% |
04-08 | Oncozenge AB Appoints Paolo Bossi as Member of the Advisory Board | CI |
04-04 | OncoZenge Announces Read-Out of Positive Stability Data for BupiZenge | CI |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+27.99% | 4.27M | |
+30.38% | 684B | |
+26.51% | 568B | |
-4.36% | 361B | |
+19.30% | 329B | |
+3.73% | 284B | |
+16.70% | 240B | |
+8.78% | 208B | |
-7.93% | 200B | |
+7.68% | 166B |
- Stock Market
- Equities
- ONCOZ Stock
- News OncoZenge AB
- OncoZenge AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022